公开(公告)号：US20240058348A1

公开(公告)日：2024-02-22

申请号：US18188716

申请日：2023-03-23

Applicant: Epizyme, Inc. ,  Eisai R&D Management Co., Ltd.

Inventor： Heike KEILHACK ,  Sarah K. KNUTSON ,  Danielle Johnston BLACKWELL ,  Larisa REYDERMAN ,  Lone OTTESEN

IPC: A61K31/5377 ,  C07D213/65 ,  C07D405/12 ,  A61K31/4412 ,  A61K31/4545

CPC classification number: A61K31/5377 ,  C07D213/65 ,  C07D405/12 ,  A61K31/4412 ,  A61K31/4545

Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.

公开(公告)号：US20220281854A1

公开(公告)日：2022-09-08

申请号：US17751153

申请日：2022-05-23

Applicant: Epizyme, Inc.

Inventor： Heike KEILHACK ,  Sarah Kathleen KNUTSON ,  Kevin Wayne KUNTZ

IPC: C07D405/12 ,  A61K45/06 ,  A61K31/436 ,  A61K31/53 ,  A61K31/573 ,  A61K31/704 ,  A61K31/7068 ,  C07D213/64 ,  A61K31/4412 ,  A61K31/5377 ,  A61K31/4439 ,  C07D413/14 ,  A61K31/444 ,  A61P35/00 ,  A61K33/243 ,  A61K31/5355 ,  A61K31/4745 ,  A61K31/675

Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

公开(公告)号：US20210121470A1

公开(公告)日：2021-04-29

申请号：US17011132

申请日：2020-09-03

Applicant: Epizyme, Inc.

Inventor： Heike KEILHACK

IPC: A61K31/5377 ,  A61K31/445 ,  A61K31/496 ,  A61K31/4412 ,  A61K31/501 ,  A61P35/00 ,  A61K31/44 ,  A61K31/4545

Abstract: The disclosure provides a method of treating a malignant rhabdoid tumor in a subject in need thereof including administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In certain embodiments of this method the malignant rhabdoid tumor is small cell cancer of the ovary of the hypercalcemic type (SCCOHT) and the EZH2 inhibitor is tazemetostat (also known as Tazemetostat).

公开(公告)号：US20210060030A1

公开(公告)日：2021-03-04

申请号：US16998144

申请日：2020-08-20

Applicant: Epizyme, Inc. ,  Eisai R&D Management Co., Ltd.

Inventor： Heike KEILHACK ,  Brett TRUITT ,  Yuta SUZUKI ,  Tsukasa MURASE ,  Futoshi SHIKATA

IPC: A61K31/5377 ,  A61K9/20 ,  A61K9/00 ,  A61K9/28

Abstract: The present invention relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).

公开(公告)号：US20200268765A1

公开(公告)日：2020-08-27

申请号：US16778274

申请日：2020-01-31

Applicant: Epizyme, Inc. ,  The Regents of the University of Colorado, A Body Corporate

Inventor： Heike KEILHACK ,  Nigel J. WATERS ,  Rajeev VIBHAKAR

IPC: A61K31/5377 ,  A61K31/4545 ,  A61K31/4412 ,  A61K31/501 ,  A61K31/4468 ,  A61K31/496 ,  A61K31/4436 ,  A61P35/00 ,  A61K9/00

Abstract: The disclosure provides a method of treating a medulloblastoma in a subject in need thereof comprising administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In a preferred embodiment of this method, the subject is pediatric and the EZH2 inhibitor is Tazemetostat.

公开(公告)号：US20190255060A1

公开(公告)日：2019-08-22

申请号：US16250211

申请日：2019-01-17

Applicant: Epizyme, Inc.

Inventor： Heike KEILHACK ,  Sarah Kathleen KNUTSON ,  Danielle Johnston BLACKWELL

IPC: A61K31/5377 ,  A61K31/704 ,  A61K31/675 ,  A61K31/573 ,  A61K31/475 ,  A61K31/4412 ,  G01N33/574 ,  A61P35/00 ,  A61K45/06 ,  A61K31/444 ,  A61K39/395

Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

公开(公告)号：US20180318309A1

公开(公告)日：2018-11-08

申请号：US15816907

申请日：2017-11-17

Applicant: Epizyme, Inc.

Inventor： Kevin W. KUNTZ ,  Richard CHESWORTH ,  Kenneth W. DUNCAN ,  Heike KEILHACK ,  Natalie WARHOLIC ,  Christine KLAUS ,  Sarah K. KNUTSON ,  Timothy J.N. WIGLE ,  Masashi SEKI ,  Syuji SHIROTORI ,  Satoshi KAWANO

IPC: A61K31/5377 ,  C07D498/08 ,  C07D213/64 ,  A61K31/444 ,  A61K31/4412 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/553 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/551 ,  C07D491/107 ,  C07D491/08 ,  C07D417/12 ,  C07D413/12 ,  C07D409/12 ,  C07D405/12 ,  C07D401/12 ,  C07D405/14

CPC classification number: A61K31/5377 ,  A61K31/4412 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/551 ,  A61K31/553 ,  C07D213/64 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D491/08 ,  C07D491/107 ,  C07D498/08

Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

公开(公告)号：US20180311251A1

公开(公告)日：2018-11-01

申请号：US15580908

申请日：2016-06-10

Applicant: Epizyme, Inc.

Inventor： Heike KEILHACK ,  Sarah K. KNUTSON ,  Danielle Johnston BLACKWELL

IPC: A61K31/5377 ,  A61P35/00 ,  A61K45/06 ,  G01N33/574

CPC classification number: A61K31/4412 ,  A61K31/444 ,  A61K31/5377 ,  A61K45/06

Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

公开(公告)号：US20240245697A1

公开(公告)日：2024-07-25

申请号：US18606925

申请日：2024-03-15

Applicant: Epizyme, Inc.

Inventor： Kevin W. KUNTZ ,  Richard CHESWORTH ,  Kenneth W. DUNCAN ,  Heike KEILHACK ,  Natalie WARHOLIC ,  Christine KLAUS ,  Sarah K. KNUTSON ,  Timothy J.N. WIGLE ,  Masashi SEKI ,  Syuji SHIROTORI ,  Satoshi KAWANO

IPC: A61K31/5377 ,  A61K31/4412 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/551 ,  A61K31/553 ,  C07D213/64 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D491/08 ,  C07D491/107 ,  C07D498/08

CPC classification number: A61K31/5377 ,  A61K31/4412 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/551 ,  A61K31/553 ,  C07D213/64 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D491/08 ,  C07D491/107 ,  C07D498/08

Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

公开(公告)号：US20240024331A1

公开(公告)日：2024-01-25

申请号：US18188706

申请日：2023-03-23

Applicant: Epizyme, Inc.

Inventor： Heike KEILHACK ,  Sarah K. Knutson

IPC: A61K31/5377 ,  A61K31/4412 ,  A61K31/4545 ,  A61P35/00 ,  A61K9/00

CPC classification number: A61K31/5377 ,  A61K31/4412 ,  A61K31/4545 ,  A61P35/00 ,  A61K9/0053

Abstract: The present disclosure relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).